Jane Street Group, LLC Enlivex Therapeutics Ltd. Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$3.81 - $8.64 $200,051 - $453,660	-52,507 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$4.92 - $6.66 $122,050 - $165,214	24,807 Added 89.56%	52,507 $294,000
Q4 2021 Feb 15, 2022	BUY	$5.81 - $9.73 $96,672 - $161,897	16,639 Added 150.43%	27,700 $173,000
Q3 2021 Nov 16, 2021	BUY	$7.43 - $13.86 $3,989 - $7,442	537 Added 5.1%	11,061 $109,000
Q2 2021 Aug 16, 2021	SELL	$8.61 - $12.1 $4,701 - $6,606	-546 Reduced 4.93%	10,524 $94,000
Q1 2021 May 18, 2021	BUY	$9.26 - $24.0 $102,508 - $265,680	11,070 New	11,070 $123,000
Q4 2020 Feb 17, 2021	SELL	$8.16 - $14.5 $88,185 - $156,701	-10,807 Closed	0 $0
Q3 2020 Nov 17, 2020	SELL	$4.64 - $5.94 $92,354 - $118,229	-19,904 Reduced 64.81%	10,807 $64,000
Q2 2020 Aug 17, 2020	BUY	$4.4 - $6.4 $135,128 - $196,550	30,711 New	30,711 $155,000
Q4 2019 Feb 14, 2020	SELL	$6.61 - $27.48 $156,359 - $650,039	-23,655 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$19.7 - $39.42 $466,003 - $932,480	23,655 New	23,655 $632,000

2.58M

20.8K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $21M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.